切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2011, Vol. 05 ›› Issue (02) : 115 -119. doi: 10.3877/cma.j.issn.1674-0793.2011.02.007

所属专题: 文献

论著

CD133、β-catenin在胰腺癌中的表达及其临床关联性
李小卫1, 姚宝忠1, 李展宇2, 杨颖秋3, 苏远航1, 岑宏1, 汤聪1,()   
  1. 1. 519000,珠海,中山大学附属第五医院普外四科
    2. 519000,珠海,中山大学附属第五医院病理科
    3. 519000,珠海,中山大学附属第五医院眼科
  • 收稿日期:2010-10-27 出版日期:2011-04-01
  • 通信作者: 汤聪

Expression of CD133 and β-catenin in pancreatic cancer and clinical relevance

Xiao-wei LI1, Bao-zhong YAO1, Zhan-yu LI2, Ying-qiu YANG3, Yuan-hang SU1, Hong CEN1, Cong TANG1,()   

  1. 1. Department of General Surgery IV, Department of Pathology, Department of Ophthalmology, the Fifth Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Zhuhai 519000, China
  • Received:2010-10-27 Published:2011-04-01
  • Corresponding author: Cong TANG
  • About author:
    Corresponding author: TANG Cong, Email:
引用本文:

李小卫, 姚宝忠, 李展宇, 杨颖秋, 苏远航, 岑宏, 汤聪. CD133、β-catenin在胰腺癌中的表达及其临床关联性[J/OL]. 中华普通外科学文献(电子版), 2011, 05(02): 115-119.

Xiao-wei LI, Bao-zhong YAO, Zhan-yu LI, Ying-qiu YANG, Yuan-hang SU, Hong CEN, Cong TANG. Expression of CD133 and β-catenin in pancreatic cancer and clinical relevance[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(02): 115-119.

目的

探讨CD133、β-catenin在胰腺癌中的表达及其临床意义。

方法

采用免疫组织化学方法(SP法)检测35例手术切除胰腺癌组织、癌旁组织、正常胰腺组织及胰周淋巴组织中CD133及β-catenin的表达情况。

结果

CD133、β-catenin在胰腺癌中的表达阳性率分别为74.3%、62.9%,显著高于癌旁组织及正常组织中的阳性率,CD133的表达与淋巴转移、病理分期有关(P<0.05)、β-catenin的表达与淋巴转移、病理分期、分化程度有关(P<0.05),两者在蛋白表达水平上有明显相关性(P<0.05),CD133阳性表达组术后生存期明显短于阴性组(P<0.05)。

结论

胰腺癌中CD133的高表达与TNM分期及淋巴结转移有关。CD133高表达与胰腺癌预后差有关。β-catenin可能通过调节CD133的表达来调节胰腺癌干细胞的某些功能。

Objective

To investigate the expression and significance of CD133 and β-catenin in pancreatic cancer and their relationship with the clinical pathologic characters.

Methods

Immunohistochemistry(SP) was used to detect the expression of CD133 and β-catenin in 35 pancreatic cancer tissues, the cancerous peripheral tissues, the normal pancreatic tissues and peripheral lymphonodes.

Results

The positive rates of CD133 and β-catenin expression in pancreatic carcinomas which were 74.3% and 62.9%, were significantly higher than that in adjacent normal tissue(P<0.05). The clinicopathological factors including pathologic staging and lymph node metastasis, were demonstrated significantly positive correlations with the expression of CD133 respectively(P<0.05). The expression of β-catenin was associated with lymph node metastasis, pathological grade and histological differentiation, it also significantly correlated with the expression of CD133 (P<0.05). Consequently, the 5-year survival rate of CD133-positive patients was significantly lower than that of CD133-negative patients (P<0.05).

Conclusions

As important moleculars in prancreatic carcinoma stem cell, both CD133 andβ-catenin play important roles in the tumorigenesis, development and metastasis of pancreatic carcinoma.β-catenin may regulate certain functions of pancreatic cancer stem cell by regulatting CD133's expression.

图1 光学显微镜下胰腺癌组织CD133阳性表达,棕色染色颗粒主要表达在细胞膜及细胞质中,以腺体周围为主(SP法,10×40)
图2 光学显微镜下胰腺癌组织CD133阴性表达,视野中无棕黄色染色颗粒(SP法,10×40)
表1 CD133、β-catenin的表达与胰腺癌临床病理因素的关系(Fisher确切概率法)
图3 光学显微镜下胰腺癌组织中β-catenin阳性表达,棕色染色颗粒主要集中表达在细胞核中,少量表达在细胞质中(SP法,10×40)
图4 光学显微镜下胰腺癌组织标本中β-catenin正常表达(阴性),视野中棕黄色染色颗粒主要集中在细胞膜上,少量位于细胞质中(SP法,10×40倍)
图5 两组生存曲线分析
1
Olempska M, Eisenach PA, Ammerpohl O, et al. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int, 2007, 6(1): 92-97.
2
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007,1(3): 313-323.
3
Wang YH, Li F, Luo B, et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma, 2009, 56(5): 371-378.
4
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res, 2007, 67(3): 1030-1037.
5
Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci, 2006, 119(7): 1453.
6
Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol, 2010, 52(6): 872-879.
7
Liu Z, Habener JF. Wnt signaling in pancreatic islets. Adv Exp Med Biol, 2010, 654: 391-419.
8
Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer, 2002, 102(4): 338-342.
9
Kolligs FT, Bommer G, Goke B. Wnt/β-catenin/tcf signaling: A critical pathway in gastrointestinal tumorigenesis. Digestion, 2002, 66(3): 131.
10
Li YJ, Wei ZM, Meng YX, et al. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol, 2005, 11(14): 2117-2123.
11
Heiser PW, Cano DA, Landsman L, et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology, 2008, 135(4): 1288-1300.
12
Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res, 2009, 19(6): 683-697.
13
Horst D, Kriegl L, Engel J, et al. CD133 and nuclear b-catenin: The marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer, 2009, 45(11): 2034-2040.
14
Smith LM, Nesterova A, Ryan MC, et al. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer, 2008, 99(1): 100-109.
15
Chen MS, Woodward WA, Behbod F, et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci, 2007, 120(Pt 3): 468-477.
[1] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[2] 陈怡芳, 黄晓卉. 肝细胞癌中对氧磷酶2的表达及临床意义[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 186-191.
[3] 刘政宏, 王凤力, 吉亚君, 高佳. 胃癌中ELK3蛋白的表达与临床病理特征和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(02): 155-159.
[4] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[5] 李博, 马秀岩, 孙杰. lncRNA TINCR对滋养层HTR-8/SVneo细胞生物学行为的影响及其机制[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 167-172.
[6] 张瑜, 姜梦妮. 基于DWI信号值构建局部进展期胰腺癌放化疗生存获益预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 657-664.
[7] 王天福, 王刚. 自身免疫性胰腺炎诊治现状[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 492-497.
[8] 孟煜凡, 李永政, 樊知遥, 展翰翔. 瘤内微生物在胰腺癌发病和演进中的作用机制及研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 577-582.
[9] 黄金灿, 王迪, 崔松平, 陈晴, 吕少诚, 贺强, 郎韧. 预后营养指数对交界可切除胰腺癌患者术后预后的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 51-56.
[10] 夏可顺, 黄耀辉, 王茂, 刘志勇, 谭博, 宋鹏, 印晓鸿. miR-145-5p抑制造釉细胞型颅咽管瘤细胞增殖、侵袭和SOX9/β-catenin表达[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(01): 6-15.
[11] 麦麦提依明·托合提, 柳叶, 张诚, 阿卜杜喀迪尔·牙森, 高峰, 王继超, 吴永刚. PEA3EPHA2在脑胶质母细胞瘤中的表达及在Wnt/β-catenin通路的作用[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(02): 73-79.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 楚海强, 杨远游, 任刚. 胰腺癌放射治疗联合其他治疗方法的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 392-396.
[14] 杨帆, 丁雪丽, 李晓宇, 宋玉君, 田字彬, 郭英杰. 高浓度尿酸盐对肠道细胞尿酸转运蛋白三磷酸腺苷结合盒转运蛋白G2表达及其功能的影响[J/OL]. 中华临床医师杂志(电子版), 2024, 18(01): 57-63.
[15] 吴子龙, 吴冰, 袁开盛, 胡瑞翔, 杨华, 王存川. 肥胖与胰腺疾病研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 213-219.
阅读次数
全文


摘要